Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

HIV Infections Clinical Trials

A listing of HIV Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (48) clinical trials

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

Recent advances in antibody cloning technologies have led to the discovery of a number of highly potent and HIV-specific broadly neutralizing monoclonal antibodies (bNAbs) from B cells of HIV-infected individuals. It has been shown that certain bNAbs can prevent acquisition of the virus, suppress viral replication, delay and/or prevent plasma ...

Phase

Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who ...

Phase

A Single Dose of Pembrolizumab in HIV-Infected People

A subset of HIV-infected patients, those with poor immunologic response to combined antiretroviral therapy (CD4+ T-cell count of less than 300-350 cells/mm^3) despite control of viremia, are at increased risk for both HIV-related and non-HIV-related complications compared to immunologic responders. Thus, novel approaches for treating HIV infection are needed to ...

Phase

Safety Tolerability Pharmacokinetics and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na ve HIV-1 Infected Participants (MK-8558-002)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-nave HIV-1 infected participants. The primary hypothesis is that at a dose that exhibits an acceptable safety and tolerability profile, MK-8558 has superior anti-retroviral activity compared to historical placebo data.

Phase

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Phase

Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas

PRIMARY OBJECTIVES: Phase I: To determine the MTD (Maximum Tolerated Dose) and select optimal biological doses (OBD) of NT-I7 in HGG patients with severe lymphopenia Pilot Study: To test the effect of NT-I7 on CD4 counts compared to control SECONDARY OBJECTIVES: To evaluate the optimal biological dose of NT-I7 To ...

Phase

Venetoclax Ibrutinib Prednisone Obinutuzumab and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Background Combination chemotherapy with Rituximab has been the mainstay of treatment for CD20- positive B-cell lymphomas Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy but indolent lymphomas and relapsed/refractory aggressive lymphomas remain mostly incurable with chemotherapy alone Targeted therapies aimed at disrupting key survival pathways in ...

Phase

Pharmacokinetics of SAR441236

This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against HIV. The study includes two arms. In Arm A, three cohorts of antiretroviral-treated, virologically suppressed participants will be randomized to receive a single intravenous (IV) dose of SAR441236 or placebo on ...

Phase

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

There are 4 study Arms as it is possible that pharmacokinetics (PK) may differ between HIV-1-uninfected individuals (Arms 1, 2 and 4) and HIV-1-infected and viremic individuals (Arm 3). Safety and tolerability as well as PK may differ between the IV and SC routes, Arms 1, 2 and 4. A ...

Phase

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

Rifapentine (RPT) is a long-acting rifamycin that can be used weekly with isoniazid (INH) as a first-line regimen in the treatment of latent tuberculosis infection (LTBI). Although this regimen offers several potential benefits, the use of weekly RPT plus INH is not currently recommended in adults infected with human immunodeficiency ...

Phase